DMT 200

Drug Profile

DMT 200

Alternative Names: DMT 210; DMT 220; DMT200; SIG 990

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Signum Biosciences
  • Developer Dermata Therapeutics; Signum Biosciences
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules; Terpenes
  • Mechanism of Action G protein-coupled receptor antagonists; GTP-binding protein modulators; Interleukin 4 inhibitors; Interleukin 6 inhibitors; Interleukin-17 inhibitors; Toll like receptor 2 antagonists; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Rosacea
  • Preclinical Acne vulgaris

Most Recent Events

  • 28 Feb 2017 Early research in Rosacea in USA (Ophthalmic) (Dermata Therapeutics pipeline, February 2017)
  • 28 Feb 2017 Preclinical trials in Acne vulgaris in USA (Topical) (Dermata Therapeutics pipeline, February 2017)
  • 01 Jan 2017 Phase-II clinical trials in Rosacea in USA (Topical) (NCT03003104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top